# HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

> **NCT03468231** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** HAIC of FOLFOX
- **DRUG:** HAIC of OXA

## Key facts

- **NCT ID:** NCT03468231
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-09
- **Primary completion:** 2019-09-09
- **Final completion:** 2020-03-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2018-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468231, "HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03468231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*